Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180115 | 1.00 | TNKS2 (0.45) | TNKS2PARP14KDM4EGAAPARP1 | |
| SCHEMBL10209684 | 0.84 | SMN1; SMN2 (0.35) | PARP14KDM4EGAAPARP1MAPT | |
| SCHEMBL22591285 | 0.83 | KDM4E (0.48) | TNKS2KDM4EGAAPARP1MAPT | |
| SCHEMBL15169214 | 0.82 | SMN1; SMN2 (0.36) | PARP14KDM4EGAAPARP1MAPT | |
| SCHEMBL10209811 | 0.82 | SMN1; SMN2 (0.36) | PARP14KDM4EGAAPARP1MAPT | |
| SCHEMBL10074706 | 0.78 | PARP1 (0.37) | PARP14KDM4EGAAPARP1MAPT | |
| SCHEMBL15180116 | 0.74 | TNKS2 (0.49) | TNKS2KDM4EGAAPARP1MAPT | |
| SCHEMBL10067671 | 0.73 | ALDH1A1 (0.42) | PARP14KDM4EGAAMAPTTDP1 | |
| SCHEMBL15180107 | 0.69 | PARP1 (0.39) | PARP14KDM4EPARP1MAPTSMN1; SMN2 | |
| SCHEMBL13842610 | 0.68 | QTRT1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | TNKS2 2774/4885PARP14 2328/4885KDM4E 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.